SCHEMBL4290660

SCHEMBL4290660

CC(C)CC(=O)Nc1ccc(C(=O)Nc2nccs2)cc1Cl

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 10/20 0.74
ADORA1 P30542 5/20 0.74
MAPK1 P28482 2/20 0.53
PIK3CD O00329 1/20 0.53
PIK3C2B O00750 1/20 0.53
AURKA O14965 1/20 0.53
PIK3C2G O75747 1/20 0.53
CDK1 P06493 1/20 0.53
CDK4 P11802 1/20 0.53
CCND1 P24385 1/20 0.53
CDK2 P24941 1/20 0.53
MAPK3 P27361 1/20 0.53
CCND3 P30281 1/20 0.53
MAPK4 P31152 1/20 0.53
PIK3CA P42336 1/20 0.53
PIK3CB P42338 1/20 0.53
PIK3CG P48736 1/20 0.53
CDK8 P49336 1/20 0.53
CDK7 P50613 1/20 0.53
CDK9 P50750 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4289795 0.88 ADORA2A (0.73) ADORA2AADORA1MAPK1RAB9ANPC1
SCHEMBL3181123 0.87 ADORA2A (0.74) ADORA2AADORA1MAPK1RAB9ANPC1
SCHEMBL4286253 0.87 ADORA2A (0.69) ADORA2AADORA1MAPK1RAB9ANPC1
SCHEMBL4299446 0.86 ADORA2A (0.75) ADORA2AADORA1MAPK1PIK3CDPIK3C2B
SCHEMBL3201177 0.85 ADORA2A (1.00) ADORA2AADORA1MAPK1PIK3CDPIK3C2B
SCHEMBL4290155 0.82 ADORA2A (1.00) ADORA2ARAB9ANPC1MEN1KMT2A
SCHEMBL3193542 0.80 ADORA2A (0.67) ADORA2AADORA1MAPK1PIK3CDPIK3C2B
Cycloheptane SCHEMBL5493970 0.80 ADORA2A (0.66) ADORA2AADORA1MAPK1PIK3CDPIK3C2B
SCHEMBL4295789 0.79 AGER (0.74) ADORA2AADORA1MAPK1RAB9ANPC1
SCHEMBL12238632 0.78 ADORA2A (0.71) ADORA2ACDK5RAB9ANPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2009-10-01 US claimed
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP claimed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP claimed
CN-1870996-A N-thiazol-2-yl-benzamide derivatives LUNDBECK & CO AS H (DK) 2006-11-29 CN claimed
EP-1682129-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-07-26 EP claimed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US claimed
WO-2005039572-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2005-05-06 WO claimed
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2009-10-01 US disclosed
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP disclosed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP disclosed
EP-1682129-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-07-26 EP disclosed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US disclosed
WO-2005039572-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885ADORA1 3/4885MAPK1 3788/4885
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885ADORA1 3/4885MAPK1 3788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.